Atreca Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.331
- Today's High:
- $0.37
- Open Price:
- $0.34
- 52W Low:
- $0.76
- 52W High:
- $2.795
- Prev. Close:
- $0.337
- Volume:
- 125612
Company Statistics
- Market Cap.:
- $40.33 million
- Book Value:
- 1.557
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -34.85%
- Return on Equity TTM:
- -93.88%
Company Profile
Atreca Inc had its IPO on 2019-06-20 under the ticker symbol BCEL.
The company operates in the Healthcare sector and Biotechnology industry. Atreca Inc has a staff strength of 90 employees.
Stock update
Shares of Atreca Inc opened at $0.34 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.33 - $0.37, and closed at $0.35.
This is a +3.86% increase from the previous day's closing price.
A total volume of 125,612 shares were traded at the close of the day’s session.
In the last one week, shares of Atreca Inc have slipped by -5.91%.
Atreca Inc's Key Ratios
Atreca Inc has a market cap of $40.33 million, indicating a price to book ratio of 0.4018 and a price to sales ratio of 0.
In the last 12-months Atreca Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-91659000. The EBITDA ratio measures Atreca Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Atreca Inc’s operating margin was 0% while its return on assets stood at -34.85% with a return of equity of -93.88%.
In Q1, Atreca Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Atreca Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.24 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Atreca Inc’s profitability.
Atreca Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1787. Its price to sales ratio in the trailing 12-months stood at 0.
Atreca Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $134.43 million
- Total Liabilities
- $14.07 million
- Operating Cash Flow
- $23.00 million
- Capital Expenditure
- $80000
- Dividend Payout Ratio
- 0%
Atreca Inc ended 2024 with $134.43 million in total assets and $0 in total liabilities. Its intangible assets were valued at $134.43 million while shareholder equity stood at $60.97 million.
Atreca Inc ended 2024 with $0 in deferred long-term liabilities, $14.07 million in other current liabilities, 4000.00 in common stock, $-477934000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $39.48 million and cash and short-term investments were $56.39 million. The company’s total short-term debt was $3,655,000 while long-term debt stood at $0.
Atreca Inc’s total current assets stands at $59.64 million while long-term investments were $0 and short-term investments were $16.90 million. Its net receivables were $409000.00 compared to accounts payable of $1.40 million and inventory worth $0.
In 2024, Atreca Inc's operating cash flow was $23.00 million while its capital expenditure stood at $80000.
Comparatively, Atreca Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.35
- 52-Week High
- $2.795
- 52-Week Low
- $0.76
- Analyst Target Price
- $8.94
Atreca Inc stock is currently trading at $0.35 per share. It touched a 52-week high of $2.795 and a 52-week low of $2.795. Analysts tracking the stock have a 12-month average target price of $8.94.
Its 50-day moving average was $0.71 and 200-day moving average was $1.07 The short ratio stood at 24.94 indicating a short percent outstanding of 0%.
Around 342.1% of the company’s stock are held by insiders while 4532.2% are held by institutions.
Frequently Asked Questions About Atreca Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.